Welcome to our dedicated page for Sensei Biotherapeutics news (Ticker: SNSE), a resource for investors and traders seeking the latest updates and insights on Sensei Biotherapeutics stock.
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) is a clinical stage biotechnology company in immuno-oncology, and the news flow around SNSE reflects its focus on cancer drug development, clinical data, and corporate strategy. The company regularly issues press releases on quarterly financial results, clinical trial milestones, capital markets actions, and strategic decisions, which are then furnished to the SEC on Form 8-K.
Recent news has centered on solnerstotug, Sensei’s lead product candidate. The company has released updates from a multi-center Phase 1/2 trial evaluating solnerstotug, a conditionally active antibody targeting the VISTA checkpoint, as monotherapy and in combination with Libtayo® (cemiplimab) in patients with advanced solid tumors. These announcements have highlighted emerging clinical signals in PD-(L)1 resistant “hot” tumors, durability of progression-free survival, safety and tolerability data, and presentations at major scientific meetings such as the ESMO Congress.
Investors following SNSE news also see corporate and financial updates, including quarterly earnings releases, commentary on research and development and general and administrative expenses, and disclosures about cash, cash equivalents, and marketable securities. Sensei has additionally reported participation in investor and scientific conferences, such as healthcare and oncology events where company representatives discuss its tumor microenvironment–focused approach.
A key development in the company’s news stream is the strategic review announced on October 30, 2025, when Sensei’s Board decided to discontinue development of solnerstotug and explore strategic alternatives that may include asset sales, licensing, collaborations, a sale of the company, a business combination, a merger, or an orderly wind-down of operations. Subsequent news has described workforce reductions and the company’s intention to retain a smaller team to manage this process and maintain regulatory and financial reporting compliance.
This news page allows readers to track these evolving themes: clinical data releases, financial results, Nasdaq listing and reverse stock split actions, and updates on the strategic alternatives process, all of which shape the ongoing story of SNSE.
Sensei Biotherapeutics (Nasdaq: SNSE), a clinical stage biotechnology company specializing in next-generation cancer therapeutics, has announced its participation in an upcoming industry event. John Celebi, President and CEO, will be a panelist in the New Radiotherapy and Targeted Therapy Approaches discussion at the Canaccord Genuity Horizons in Oncology Virtual Conference. The panel is scheduled for Monday, April 7 at 2:00 p.m. ET.
Sensei Biotherapeutics (NASDAQ: SNSE) reported its full year 2024 financial results and clinical progress for solnerstotug, their conditionally active antibody targeting VISTA. Key clinical highlights include:
In the Phase 1/2 dose expansion study, among 21 evaluable PD-(L)1 resistant tumor patients, the combination therapy showed 14% overall response rate (3x higher than historical rates) and 62% disease control rate. The study achieved target enrollment of 60 patients, with full expansion data expected by year-end 2025.
Financial results show:
- Cash position: $41.3M as of December 31, 2024
- R&D expenses: $18.6M (vs $18.3M in 2023)
- G&A expenses: $13.0M (vs $18.8M in 2023)
- Net loss: $30.2M (vs $34.1M in 2023)
The company expects its current cash runway to extend into Q2 2026.
Sensei Biotherapeutics (NASDAQ: SNSE) has reported promising preliminary results from its Phase 1/2 trial of solnerstotug, a conditionally active antibody targeting VISTA. The drug showed significant clinical activity in PD-(L)1 resistant tumors, achieving a 14% overall response rate - nearly triple the historical rechallenge rates of ≤5%.
Key findings include:
- One durable complete response in Merkel Cell Carcinoma (MCC)
- Two partial responses in MCC and MSI-H Colorectal Cancer patients
- 62% disease control rate among 21 evaluable PD-(L)1 resistant patients
- All patients with tumor shrinkage remain on treatment
The drug demonstrated favorable safety with no dose-limiting toxicities, mostly Grade 1-2 adverse events, and only 7% cases of mild cytokine release syndrome. Subject to capital raising, Sensei plans to initiate Phase 2 studies in Q1 2026.
Sensei Biotherapeutics (Nasdaq: SNSE), a clinical stage biotechnology company specializing in next-generation cancer therapeutics, has announced its participation in Oppenheimer's 35th Annual Healthcare Life Sciences Conference. The company's President and CEO, John Celebi, will deliver a presentation at the virtual event on Tuesday, February 11, 2025, at 10:40 a.m. ET.
Interested parties can access the presentation webcast through the Investors section of Sensei's website. The replay will remain available for approximately 90 days after the event, and registration for the webcast is currently open.
Sensei Biotherapeutics (NASDAQ: SNSE) provided updates on its lead program, solnerstotug (SNS-101), a conditionally active antibody targeting VISTA in cancer treatment. The company has enrolled 45 patients in the dose expansion portion of its Phase 1/2 clinical trial, with full enrollment of approximately 60 patients expected by Q1 2025.
The trial evaluates solnerstotug both as monotherapy and in combination with Libtayo® in patients with advanced solid tumors. Most enrolled 'hot' tumor patients have either progressed on prior anti-PD-1 therapy or are PD-L1 negative. The drug continues to show good tolerability with a best-in-class pharmacokinetic profile, with dose optimization focusing on 3 and 15 mg/kg Q3W levels.
Clinical data update is expected in Q2 2025, including patient follow-up data from dose escalation cohorts. The company maintains cash runway into Q2 2026.
Sensei Biotherapeutics (Nasdaq: SNSE) announced its participation in Citi's 2024 Global Healthcare Conference. The conference will take place from December 3-5 in Miami, FL. As a clinical stage biotechnology company specializing in next-generation cancer therapeutics, Sensei's management team will be present at this significant healthcare industry event.
Sensei Biotherapeutics (NASDAQ: SNSE) reported Q3 2024 financial results and announced an organizational restructuring. The company will reduce its workforce by 46% and close its Rockville research site to focus resources on SNS-101 clinical development. Cash position stands at $47.0 million, expected to fund operations into Q2 2026. Q3 net loss was $7.3 million, with R&D expenses at $4.6 million and G&A expenses at $3.2 million. The Phase 1/2 dose expansion study for SNS-101 is approximately 50% enrolled, with clinical data expected in H1 2025.
Sensei Biotherapeutics (Nasdaq: SNSE) has announced its participation in two major scientific conferences. At PEGS Europe in Barcelona (November 5-7, 2024), Chief Scientific Officer Edward van der Horst will present on SNS-101, a conditionally active monoclonal antibody targeting VISTA in tumor microenvironment. At the SITC 39th Annual Meeting in Houston (November 6-10, 2024), Senior Director F. Donelson Smith will present a poster on spatial proteomic profiling of VISTA and PSGL-1 interactions across cancer indications.